ASLAN Pharmaceuticals Ltd (ASLN) Stock Earnings & Estimates
USA - NASDAQ:ASLN - US04522R2004 - ADR
0.6 USD
-0.1 (-14.27%)
0.56 USD
-0.04 (-6.67%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 3M | -100.00% | 12.24M | -100.00% | 58.856M | 502.56M 753.88% | 1.095B 117.88% | |||||||
| EBITDA YoY % growth | -38.78M | -42.1M -8.56% | -22.07M 47.58% | N/A 26.69% | N/A -107.48% | N/A -41.65% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -38.99M -347.13% | -42.35M -8.62% | -22.51M 46.85% | -14.621M 26.79% | -32.663M -105.40% | -46.832M -41.45% | -42.701M 10.82% | -61.501M -44.03% | -52.02M 15.42% | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | -750.33% | N/A | N/A | N/A | -348.87% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -1.38 | -1.43 -3.47% | -1.99 68.32% | -2.43 -146.70% | -3.60 -233.93% | -2.66 -119.25% | -3.41 58.45% | -2.40 29.64% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.67 -3,238.18% | -0.48 14.39% | -1.86 70.25% | -0.56 86.77% | -0.59 83.89% | -0.61 -27.66% | -0.64 65.38% |
| Revenue Q2Q % growth | -100.00% | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.322M -378.86% | -11.577M -11.09% | -27.387M -144.65% | -11.985M -6.86% | -12.75M -12.61% | -13.26M -14.54% | -14.025M 48.79% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -4.24 -228.68% | -4.98 | 0.74 | 14.82% |
| Q4 2023 Q2Q % growth | -6.24 -500.00% | -5.30 | -0.94 | -17.65% |
| Q3 2023 Q2Q % growth | -0.56 30.00% | -0.80 | 0.24 | 29.61% |
| Q2 2023 Q2Q % growth | -0.11 88.42% | -0.82 | 0.71 | 86.52% |
| Q1 2023 Q2Q % growth | -1.29 -35.79% | -4.13 | 2.84 | 68.77% |
| Q4 2022 Q2Q % growth | -1.04 -30.00% | -0.91 | -0.13 | -14.56% |
| Q3 2022 Q2Q % growth | -0.80 -566.67% | -0.97 | 0.17 | 17.44% |
| Q2 2022 Q2Q % growth | -0.95 -1,257.14% | -1.02 | 0.07 | 6.86% |
| Q1 2022 Q2Q % growth | -0.95 -630.77% | -0.92 | -0.03 | -3.49% |
| Q4 2021 Q2Q % growth | -0.80 -433.33% | -0.73 | -0.07 | -9.44% |
| Q3 2021 Q2Q % growth | -0.12 -20.00% | -0.13 | 0.01 | 9.50% |
| Q2 2021 Q2Q % growth | -0.07 32.69% | -0.11 | 0.04 | 37.61% |
| Q1 2021 Q2Q % growth | -0.13 -30.00% | -0.11 | -0.02 | -15.86% |
| Q4 2020 Q2Q % growth | -0.15 83.33% | -0.10 | -0.05 | -47.06% |
| Q3 2020 Q2Q % growth | -0.10 33.33% | -0.10 | 0.00 | -3.20% |
| Q2 2020 Q2Q % growth | -0.10 58.06% | -0.08 | -0.02 | -27.45% |
| Q1 2020 Q2Q % growth | -0.10 25.93% | -0.08 | -0.02 | -22.55% |
| Q4 2019 Q2Q % growth | -0.90 | -0.17 | -0.73 | -419.03% |
| Q3 2019 Q2Q % growth | -0.15 | -0.23 | 0.08 | 36.06% |
| Q2 2019 Q2Q % growth | -0.25 | -0.20 | -0.04 | -21.57% |
| Q1 2019 Q2Q % growth | -0.14 | -0.18 | 0.05 | 26.47% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2020 Q2Q % growth | -100.00% | % | ||
| Q1 2019 Q2Q % growth | 3M | 1.938M | 1.062M | 54.80% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | N/A | N/A | 0% | 0% |